Effect of biocompatible peritoneal dialysis solution on residual renal function: A systematic review of randomized controlled trials

Peritoneal Dialysis International

Volumn 34, Issue 7, 2014, Pages 724-731

  Seo, Eun Young ^a   An, Sook Hee ^b   Cho, Jang Hee ^c   Suh, Hae Sun ^d   Park, Sun Hee ^c   Gwak, Hyesun ^a   Kim, Yong Lim ^c   Ha, Hunjoo ^a  

^a Ewha Womans University   (South Korea)

^b Wonkwang University   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Peritoneal dialysis solutions; Randomized controlled trials; Residual renal function; Systematic review

Indexed keywords

DIALYSIS FLUID; GLUCOSE; BIOMATERIAL;

ARTICLE; BIOCOMPATIBILITY; CREATININE CLEARANCE; HUMAN; KIDNEY FUNCTION; METABOLIC PARAMETERS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDUAL RENAL FUNCTION; SYSTEMATIC REVIEW; UREA CLEARANCE; ADVERSE EFFECTS; CAUSE OF DEATH; FEMALE; FOLLOW UP; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MALE; MORTALITY; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; SURVIVAL; TREATMENT OUTCOME;

BIOCOMPATIBLE MATERIALS; CAUSE OF DEATH; DIALYSIS SOLUTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; PERITONEAL DIALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPUBLIC OF KOREA; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84928237787     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2012.00331     Document Type: Article

References (48)

1. Wang AY, Woo J, Wang M, Sea MM, Sanderson JE, Lui SF, et al. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renalfunction. Nephrol Dial Transplant 2005; 20:396-403.
2. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. JAm Soc Nephrol 2001; 12:2158-62.
3. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT. Therelativeimportance of residual renalfunction compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NEC0SAD)-2. Am J Kidney Dis 2003; 41:1293-302.
4. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang SM, Zhu X, Lazarus JM. Associates of mortality among peritoneal dialysis patients with special reference to peritonealtransport rates and solute clearance. Am J Kidney Dis 1999; 33:523-34.
5. Han SH, Ahn SV, Yun JY, Tranaeus A, Han DS. Mortality andtechniquefailurein peritonealdialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis 2009; 54:711-20.
6. Rocco M, Soucie JM, Pastan S, McClellan WM. Peritoneal dialysis adequacy and risk of death. Kidney Int 2000; 58:446-57.
7. Liao CT, Chen YM, Shiao CC, Hu FC, Huang JW, Kao TW, et al. Rate of decline of residual renalfunction is associated with all-cause mortalityandtechniquefailurein patients on long-term peritoneal dialysis. Nephrol Dial Transplant 2009; 24:2909-14.
8. Miiller-krebs S, Kihm LP, Zeier B, Gross ML, Wieslander A, Haug U, et al. Glucose degradation products result in cardiovascular toxicity in a rat model of renalfailure. Perit Dial Int 2010; 30:35-40.
9. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, et al. Damagetotheperitonealmembraneby glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17:199-207.
10. Welten AG, Schalkwijk CG, ter Wee PM, Meijer S, van den Born J, Beelen RJ. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflam-matory response. Perit Dial Int 2003; 23:213-21.
11. Erixon M, Wieslander A, Linden T, Carlsson O, Jönsson JA, Simonsen O, et al. 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into theperitonealcavity cannot be found in plasma. Perit Dial Int 2009; 29(Suppl 2):28-31.
12. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. JAm Soc Nephrol 2000; 11:729-39.
13. Chetyrkin SV, Zhang W, Hudson BG, Serianni AS, Voziyan PA. Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Biochemistry 2008; 47:997-1006.
14. Lee HK, Seo IA, Suh DJ, Lee HJ, Park HT. A novel mechanism of methylglyoxal cytotoxicity in neuroglial cells. J Neurochem 2009; 108:273-84.
15. Catalan MP, Santamaria B, Reyero A, Ortiz A, Egido J, Ortiz A. 3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney Int 2005; 68:1303-11.
16. Justo P, Sanz AB, Egido J, Ortiz A. 3,4-dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005; 54:2424-9.
17. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A. 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002; 62:697-703.
18. Ikehara O, Nishimura H, Naito T, Higuchi C, Sanaka T. Effects of neutral pH and reduced glucose degradation products in a new peritoneal dialysis solution on morphology of peritoneal membrane in rats. Nephron Exp Nephrol 2005; 100:e30-9.
19. Tomo T. Peritoneal dialysis solutions low in glucose degradation products-evidenceforclinicalbenefits. Perit Dial Int 2008; 28(Suppl 3):123-7.
20. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59:1529-38.
21. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-A 1-year randomized controltrial. Nephrol Dial Transplant 2007; 22:552-9.
22. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408-18.
23. Park SH, Do JY, Kim YH, Lee HY, Kim BS, Shin SK, et al. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study. Nephrol Dial Transplant 2012; 27:1191-9.
24. Haag-Weber M, Kramer R, Haake R, Islam MS, Prischl F, Haug U, et al. Low-GDP fluid (Gambrosol trio") attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 2010;25:2288-96.
25. Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24:2899-908.
26. Choi HY, Kim DK, Lee TH, Moon SJ, Han SH, Lee JE, et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. PeritDiallnt 2008; 28:174-82.
27. Fan SL, Pile T, Punzalan S, Raftery MJ, Vaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effecton residualrenalfunction. Kidney Int 2008; 73:200-6.
28. Kim S, Oh KH, Oh J, Kim SJ, Chung W, Song YR, et al. Biocompatible peritoneal dialysis solution preserves residual renal function. American Journal of Nephrology 2012;36:305-16.
29. Lai KN, Lam MF, Leung JC, Chan LY, Lam CW, Chan IH, et al. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Perit Dial Int 2012; 32:280-91.
30. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23:1097-107.
31. Theodoridis M, Tziakas D, Passadakis P, Kantartzi K, Roumeliotis A, Thodis E, et al. The effect of bicarbonate peritoneal dialysis solutions on cardiac structural and functional alterations. Nephrol Dial Transplant 2011; 26:4061-7.
32. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survivalfor continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Diallnt 2005; 25:248-55.
33. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0., The Cochrane Collaboration, 2011. [Available at: http://www.cochrane-handbook.org]
34. Kim SG, Kim S, Hwang YH, Kim K, Oh JE, Chung W, et al. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study). Perit Dial Int 2008; 28(Suppl 3):117-22.
35. van Olden RW, Krediet RT, Struijk DG, Arisz L. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1996; 7:745-8.
36. le Poole CY, vanlttersum FJ, Weijmer MC, Valentijn RM, ter Wee PM. Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Adv Perit Dial 2004; 20:170-6.
37. Johnson DW, Clarke M, Wilson V, Woods F, Brown FG. Rationale and design of the baLANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residualrenalfunction. BMC Nephrol 2010; 11:1-7.
38. Tom P. Effect of low glucose degradation product peritoneal dialysis solution Gambrosol-Trio on residual renal function in patients receiving peritoneal dialysis - a randomized controlled trial. Cochrane Database Syst Rev. [Available at: http://www.thecochranelibrary.com]
39. Brown F, Johnson DW. A randomized controlled trial to determine whether treatment with a neutral pH, low glucose degradation product dialysate (balance) prolongs residualrenalfunction in peritoneal dialysis patients. Pent Diallnt 2006;26:112-3.
40. Woodrow G. A randomized controlled trial to determine whether treatment with a neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients. Perit Dial Int 2006; 26:113-4.
41. Lui SL, Yung S, Yim A, Wong KM, Tong KL, Wong KS, et al. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. Am J Kidney Dis 2012; 60:966-75.
42. Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, et al. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 2009; 29:647-55.
43. Bajo MA, Perez-Lozano ML, Albar-Vizcaino P, Peso G, Castro MJ, Gonzalez-Mateo G, et al. Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothe-lial cells than a standard fluid. Nephrol Dial Transplant 2011;26:282-91.
44. Cho KH, Do JY, Park JW, Yoon KW, Kim YL. The effect of low-GDP solution on ultrafiltration and solute transport in continuous ambulatory peritoneal dialysis patients. Pent Dial Int 2013; 33:382-90.
45. Cho Y, Johnson DW, Badve SV, Craig JC, Strippoli GF, Wiggins KJ.Theimpactof neutral-pH peritonealdialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney Int 2013; 84:969-79.
46. Locatelli F, La Milia V. Preservation of residual renal function in peritoneal dialysis patients: still a dream? Kidney Int 2008; 73:143-5.
47. Davies SJ. Preserving residualrenalfunction in peritoneal dialysis: volume or biocompatibility? Nephrol Dial Transplant 2009; 24:2620-2.
48. Blake PG, Jain AK, Yohann S. Biocompatible peritoneal dialysis solutions: many questions but few answers. Kidney Int 2013; 84:864-6.